메뉴 건너뛰기




Volumn 67, Issue 12, 2007, Pages 1339-1353

The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers

Author keywords

GHRH antagonists; LHRH antagonists; Prostate cancer

Indexed keywords

ANDROGEN; CETRORELIX; D 20762; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; MZ J 7 118; MZ J 7 138; TESTOSTERONE; UNCLASSIFIED DRUG;

EID: 34548724461     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20605     Document Type: Article
Times cited : (20)

References (56)
  • 3
    • 33846412644 scopus 로고    scopus 로고
    • Hypothalamic and other peptide hormones
    • Holland JF, Frei E III, Bast RC, Jr, editors, 7th edition. Hamilton, Ontario, BC: Decker
    • Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In: Holland JF, Frei E III, Bast RC, Jr., editors. Cancer medicine. 7th edition. Hamilton, Ontario, BC: Decker 2006. 802-816.
    • (2006) Cancer medicine , pp. 802-816
    • Schally, A.V.1    Comaru-Schally, A.M.2
  • 4
    • 0026692109 scopus 로고
    • Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice
    • Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Cancer Res 1992;52: 2538-2544.
    • (1992) Cancer Res , vol.52 , pp. 2538-2544
    • Redding, T.W.1    Schally, A.V.2    Radulovic, S.3    Milovanovic, S.4    Szepeshazi, K.5    Isaacs, J.T.6
  • 5
    • 0032538353 scopus 로고    scopus 로고
    • Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors
    • Lamharzi N, Schally AV, Koppan M. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Regul Pept 1998;77: 185-192.
    • (1998) Regul Pept , vol.77 , pp. 185-192
    • Lamharzi, N.1    Schally, A.V.2    Koppan, M.3
  • 6
    • 0031876636 scopus 로고    scopus 로고
    • Lamharzi N, Halmos G, Jungwirth A, Schally AV. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist Cetrorelix in DU-145 prostate tumor xenografts in nude mice. Int J Oncol 1998;13:429-435.
    • Lamharzi N, Halmos G, Jungwirth A, Schally AV. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist Cetrorelix in DU-145 prostate tumor xenografts in nude mice. Int J Oncol 1998;13:429-435.
  • 7
    • 0030814022 scopus 로고    scopus 로고
    • Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II
    • Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, Groot K, Vadillo-Buenfil M, Schally AV. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer 1997;33:1141-1148.
    • (1997) Eur J Cancer , vol.33 , pp. 1141-1148
    • Jungwirth, A.1    Pinski, J.2    Galvan, G.3    Halmos, G.4    Szepeshazi, K.5    Cai, R.Z.6    Groot, K.7    Vadillo-Buenfil, M.8    Schally, A.V.9
  • 8
    • 0030751523 scopus 로고    scopus 로고
    • Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice
    • Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate 1997;32:164-172.
    • (1997) Prostate , vol.32 , pp. 164-172
    • Jungwirth, A.1    Galvan, G.2    Pinski, J.3    Halmos, G.4    Szepeshazi, K.5    Cai, R.Z.6    Groot, K.7    Schally, A.V.8
  • 9
    • 0035834049 scopus 로고    scopus 로고
    • Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist Triptorelin on the gene expression of pituitary LHRH receptors in rats
    • Kovacs M, Schally AV. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist Triptorelin on the gene expression of pituitary LHRH receptors in rats. Proc Natl Acad Sci USA 2001;98:12197-12202.
    • (2001) Proc Natl Acad Sci USA , vol.98 , pp. 12197-12202
    • Kovacs, M.1    Schally, A.V.2
  • 11
    • 0032739426 scopus 로고    scopus 로고
    • Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis
    • Schally AV. Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis. Peptides 1999;20:1247-1262.
    • (1999) Peptides , vol.20 , pp. 1247-1262
    • Schally, A.V.1
  • 12
    • 0032052309 scopus 로고    scopus 로고
    • Effects of LHRH-analogues on mitogenic signal transduction in cancer cells
    • Emons G, Muller V, Ortmann O, Schulz KD. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol 1998;65(1-6):199-206.
    • (1998) J Steroid Biochem Mol Biol , vol.65 , Issue.1-6 , pp. 199-206
    • Emons, G.1    Muller, V.2    Ortmann, O.3    Schulz, K.D.4
  • 13
    • 0034242518 scopus 로고    scopus 로고
    • Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix
    • Halmos G, Schally AV, Kahan Z. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix. Int J Oncol 2000;17:367-373.
    • (2000) Int J Oncol , vol.17 , pp. 367-373
    • Halmos, G.1    Schally, A.V.2    Kahan, Z.3
  • 15
    • 0029240272 scopus 로고
    • Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord
    • Gonzalez-Barcena D, Vadillo-Buenfil M, Cortez-Morales A, Fuentes-Garcia M, Cardenas-Cornejo I, Comaru-Schally AM, Schally AV. Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology 1995;45:275-281.
    • (1995) Urology , vol.45 , pp. 275-281
    • Gonzalez-Barcena, D.1    Vadillo-Buenfil, M.2    Cortez-Morales, A.3    Fuentes-Garcia, M.4    Cardenas-Cornejo, I.5    Comaru-Schally, A.M.6    Schally, A.V.7
  • 16
    • 0033485288 scopus 로고    scopus 로고
    • Antagonistic analogs of growth hormone-releasing hormone: New potential antitumor agents
    • Schally AV, Varga JL. Antagonistic analogs of growth hormone-releasing hormone: New potential antitumor agents. Trends Endocrinol Metab 1999;10:383-391.
    • (1999) Trends Endocrinol Metab , vol.10 , pp. 383-391
    • Schally, A.V.1    Varga, J.L.2
  • 17
    • 0033955413 scopus 로고    scopus 로고
    • Deregulated expression of growth factors and their receptors in the development of prostate cancer
    • Djakiew D. Deregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000;42:150-160.
    • (2000) Prostate , vol.42 , pp. 150-160
    • Djakiew, D.1
  • 18
    • 0037092971 scopus 로고    scopus 로고
    • Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease
    • Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002;62: 2942-2950.
    • (2002) Cancer Res , vol.62 , pp. 2942-2950
    • Hellawell, G.O.1    Turner, G.D.2    Davies, D.R.3    Poulsom, R.4    Brewster, S.F.5    Macaulay, V.M.6
  • 19
    • 0028113415 scopus 로고
    • Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
    • Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-5478.
    • (1994) Cancer Res , vol.54 , pp. 5474-5478
    • Culig, Z.1    Hobisch, A.2    Cronauer, M.V.3    Radmayr, C.4    Trapman, J.5    Hittmair, A.6    Bartsch, G.7    Klocker, H.8
  • 21
    • 0038758829 scopus 로고    scopus 로고
    • New advances on prostate carcinogenesis and therapies: Involvement of EGF-EGF-R transduction system
    • Mimeault M, Pommery N, Henichart JP. New advances on prostate carcinogenesis and therapies: Involvement of EGF-EGF-R transduction system. Growth Factors 2003;21:1-14.
    • (2003) Growth Factors , vol.21 , pp. 1-14
    • Mimeault, M.1    Pommery, N.2    Henichart, J.P.3
  • 22
    • 0035496220 scopus 로고    scopus 로고
    • The development of androgen-independent prostate cancer
    • Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
    • (2001) Nat Rev Cancer , vol.1 , pp. 34-45
    • Feldman, B.J.1    Feldman, D.2
  • 23
    • 0034234650 scopus 로고    scopus 로고
    • Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways
    • Plonowski A, Schally AV, Varga JL, Rekasi Z, Hebert F, Halmos G, Groot K. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate 2000;44:172-180.
    • (2000) Prostate , vol.44 , pp. 172-180
    • Plonowski, A.1    Schally, A.V.2    Varga, J.L.3    Rekasi, Z.4    Hebert, F.5    Halmos, G.6    Groot, K.7
  • 24
    • 0036680275 scopus 로고    scopus 로고
    • Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: Lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor
    • Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, Groot K, Varga JL. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: Lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor. Prostate 2002;52(3):173-182.
    • (2002) Prostate , vol.52 , Issue.3 , pp. 173-182
    • Plonowski, A.1    Schally, A.V.2    Letsch, M.3    Krupa, M.4    Hebert, F.5    Busto, R.6    Groot, K.7    Varga, J.L.8
  • 25
    • 0037417815 scopus 로고    scopus 로고
    • Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers
    • Letsch M, Schally AV, Busto R, Bajo AM, Varga JL. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci USA 2003;100:1250-1255.
    • (2003) Proc Natl Acad Sci USA , vol.100 , pp. 1250-1255
    • Letsch, M.1    Schally, A.V.2    Busto, R.3    Bajo, A.M.4    Varga, J.L.5
  • 26
    • 22144492242 scopus 로고    scopus 로고
    • Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers
    • Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate 2005;64:303-315.
    • (2005) Prostate , vol.64 , pp. 303-315
    • Stangelberger, A.1    Schally, A.V.2    Varga, J.L.3    Hammann, B.D.4    Groot, K.5    Halmos, G.6    Cai, R.Z.7    Zarandi, M.8
  • 27
    • 0034641750 scopus 로고    scopus 로고
    • Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers
    • Rekasi Z, Czompoly T, Schally AV, Halmos G. Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci USA 2000;97:10561-10566.
    • (2000) Proc Natl Acad Sci USA , vol.97 , pp. 10561-10566
    • Rekasi, Z.1    Czompoly, T.2    Schally, A.V.3    Halmos, G.4
  • 28
    • 0037039396 scopus 로고    scopus 로고
    • Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs
    • Kiaris H, Schally AV, Busto R, Halmos G, Artavanis-Tsakonas S, Varga JL. Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs. Proc Natl Acad Sci USA 2002;99:196-200.
    • (2002) Proc Natl Acad Sci USA , vol.99 , pp. 196-200
    • Kiaris, H.1    Schally, A.V.2    Busto, R.3    Halmos, G.4    Artavanis-Tsakonas, S.5    Varga, J.L.6
  • 29
    • 0034797098 scopus 로고    scopus 로고
    • A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines
    • Chopin LK, Herington AC. A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines. Prostate 2001;49:116-121.
    • (2001) Prostate , vol.49 , pp. 116-121
    • Chopin, L.K.1    Herington, A.C.2
  • 30
    • 0036776259 scopus 로고    scopus 로고
    • Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer
    • Halmos G, Schally AV, Czompoly T, Krupa M, Varga JL, Rekasi Z. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. J Clin Endocrinol Metab 2002;87:4707-4714.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 4707-4714
    • Halmos, G.1    Schally, A.V.2    Czompoly, T.3    Krupa, M.4    Varga, J.L.5    Rekasi, Z.6
  • 31
    • 0032555287 scopus 로고    scopus 로고
    • Growth hormone-releasing hormone antagonist MZ-5-156inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors
    • Lamharzi N, Schally AV, Koppan M, Groot K. Growth hormone-releasing hormone antagonist MZ-5-156inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc Natl Acad Sci USA 1998;95:8864-8868.
    • (1998) Proc Natl Acad Sci USA , vol.95 , pp. 8864-8868
    • Lamharzi, N.1    Schally, A.V.2    Koppan, M.3    Groot, K.4
  • 32
    • 1642473188 scopus 로고    scopus 로고
    • Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumor growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers
    • Letsch M, Schally AV, Stangelberger A, Groot K, Varga JL. Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumor growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers. Eur J Cancer 2004;40:436-444.
    • (2004) Eur J Cancer , vol.40 , pp. 436-444
    • Letsch, M.1    Schally, A.V.2    Stangelberger, A.3    Groot, K.4    Varga, J.L.5
  • 36
    • 33645851038 scopus 로고    scopus 로고
    • Antagonists of growth hormone-releasing hormone in oncology
    • Schally AV, Varga JL. Antagonists of growth hormone-releasing hormone in oncology. Comb Chem High Throughput Screen. 2006;9:163-170.
    • (2006) Comb Chem High Throughput Screen , vol.9 , pp. 163-170
    • Schally, A.V.1    Varga, J.L.2
  • 37
    • 0037039710 scopus 로고    scopus 로고
    • Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207
    • Plonowski A, Schally AV, Nagy A, Groot K, Krupa M, Navone NM, Logothetis C. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett 2002;176:57-63.
    • (2002) Cancer Lett , vol.176 , pp. 57-63
    • Plonowski, A.1    Schally, A.V.2    Nagy, A.3    Groot, K.4    Krupa, M.5    Navone, N.M.6    Logothetis, C.7
  • 40
    • 0031016389 scopus 로고    scopus 로고
    • Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095
    • Halmos G, Schally AV. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095. Proc Natl Acad Sci USA 1997;94:956-960.
    • (1997) Proc Natl Acad Sci USA , vol.94 , pp. 956-960
    • Halmos, G.1    Schally, A.V.2
  • 41
    • 0033963203 scopus 로고    scopus 로고
    • High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers
    • Halmos G, Arencibia JM, Schally AV, Davis R, Bostwick DG. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2000;163:623-629.
    • (2000) J Urol , vol.163 , pp. 623-629
    • Halmos, G.1    Arencibia, J.M.2    Schally, A.V.3    Davis, R.4    Bostwick, D.G.5
  • 42
    • 0030979558 scopus 로고    scopus 로고
    • Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone
    • Jungwirth A, Schally AV, Pinski J, Halmos G, Groot K, Armatis P, Vadillo-Buenfil M. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer 1997;75:1585-1592.
    • (1997) Br J Cancer , vol.75 , pp. 1585-1592
    • Jungwirth, A.1    Schally, A.V.2    Pinski, J.3    Halmos, G.4    Groot, K.5    Armatis, P.6    Vadillo-Buenfil, M.7
  • 43
  • 44
    • 0035996854 scopus 로고    scopus 로고
    • Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers
    • Plonowski A, Schally AV, Busto R, Krupa M, Varga JL, Halmos G. Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers. Peptides 2002;23:1127-1133.
    • (2002) Peptides , vol.23 , pp. 1127-1133
    • Plonowski, A.1    Schally, A.V.2    Busto, R.3    Krupa, M.4    Varga, J.L.5    Halmos, G.6
  • 45
    • 0034898083 scopus 로고    scopus 로고
    • Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide
    • Rekasi Z, Schally AV, Plonowski A, Czompoly T, Csernus B, Varga JL. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide. Prostate 2001;48:188-199.
    • (2001) Prostate , vol.48 , pp. 188-199
    • Rekasi, Z.1    Schally, A.V.2    Plonowski, A.3    Czompoly, T.4    Csernus, B.5    Varga, J.L.6
  • 46
    • 0034455291 scopus 로고    scopus 로고
    • Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: Evidence from in vitro studies on human prostatic and pancreatic cancers
    • Rekasi Z, Varga JL, Schally AV, Halmos G, Armatis P, Groot K, Czompoly T. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: Evidence from in vitro studies on human prostatic and pancreatic cancers. Endocrinology 2000; 141:2120-2128.
    • (2000) Endocrinology , vol.141 , pp. 2120-2128
    • Rekasi, Z.1    Varga, J.L.2    Schally, A.V.3    Halmos, G.4    Armatis, P.5    Groot, K.6    Czompoly, T.7
  • 47
    • 0035182258 scopus 로고    scopus 로고
    • Schally AV, Halmos G, Rekasi Z, Arencibia JM. The actions of luteinizing hormone releasing hormone agonists, antagonists, and cytotoxic analogs on the luteinizing hormone releasing hormone receptors on the pituitary and tumors. Devroey P., ed. 12; Saunders, Philadelphia: Infertility and Reproductive Medicine Clinics of North America: GnRH Analogue; 2001; pp 17-44.
    • Schally AV, Halmos G, Rekasi Z, Arencibia JM. The actions of luteinizing hormone releasing hormone agonists, antagonists, and cytotoxic analogs on the luteinizing hormone releasing hormone receptors on the pituitary and tumors. Devroey P., ed. Vol. 12; Saunders, Philadelphia: Infertility and Reproductive Medicine Clinics of North America: GnRH Analogue; 2001; pp 17-44.
  • 48
    • 0032584108 scopus 로고    scopus 로고
    • Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells
    • Okada F, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L, Shirasawa S, Sasazuki T, Kerbel RS. Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 1998;95: 3609-3614.
    • (1998) Proc Natl Acad Sci USA , vol.95 , pp. 3609-3614
    • Okada, F.1    Rak, J.W.2    Croix, B.S.3    Lieubeau, B.4    Kaya, M.5    Roncari, L.6    Shirasawa, S.7    Sasazuki, T.8    Kerbel, R.S.9
  • 50
    • 0028910567 scopus 로고
    • Consequences of angiogenesis for tumor progression, metastasis and cancer therapy
    • Rak JW, St. Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 1995;6:3-18.
    • (1995) Anticancer Drugs , vol.6 , pp. 3-18
    • Rak, J.W.1    St. Croix, B.D.2    Kerbel, R.S.3
  • 51
    • 0030500444 scopus 로고    scopus 로고
    • Vascular endothelial growth factor
    • Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996; 32a:2413-2422.
    • (1996) Eur J Cancer , vol.32 a , pp. 2413-2422
    • Ferrara, N.1
  • 53
    • 0032821184 scopus 로고    scopus 로고
    • Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs
    • Szepeshazi K, Halmos G, Schally AV, Arencibia JM, Groot K, Vadillo-Buenfil M, Rodriguez-Martin E. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. J Cancer Res Clin Oncol 1999;125:444-452.
    • (1999) J Cancer Res Clin Oncol , vol.125 , pp. 444-452
    • Szepeshazi, K.1    Halmos, G.2    Schally, A.V.3    Arencibia, J.M.4    Groot, K.5    Vadillo-Buenfil, M.6    Rodriguez-Martin, E.7
  • 54
    • 27744575622 scopus 로고    scopus 로고
    • Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of Bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signaling
    • Stangelberger A, Schally AV, Varga JL, Zarandi M, Cai RZ, Baker B, Hammann BD, Armatis P, Kanashiro CA. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of Bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signaling. Eur J Cancer 2005;41:2735-2744.
    • (2005) Eur J Cancer , vol.41 , pp. 2735-2744
    • Stangelberger, A.1    Schally, A.V.2    Varga, J.L.3    Zarandi, M.4    Cai, R.Z.5    Baker, B.6    Hammann, B.D.7    Armatis, P.8    Kanashiro, C.A.9
  • 55
    • 0022489875 scopus 로고
    • Early events elicited by Bombesin and structurally related peptides in quiescent Swiss 3TC cells. I. Activation of protein kinase C and inhibition of epidermal growth factor binding
    • Zachary I, Sinnett-Smith JW, Rozengurt E. Early events elicited by Bombesin and structurally related peptides in quiescent Swiss 3TC cells. I. Activation of protein kinase C and inhibition of epidermal growth factor binding. J Cell Biol 1986;102:2211-2222.
    • (1986) J Cell Biol , vol.102 , pp. 2211-2222
    • Zachary, I.1    Sinnett-Smith, J.W.2    Rozengurt, E.3
  • 56
    • 0026071869 scopus 로고    scopus 로고
    • Lee MT, Liebow C, Kamer AR, Schally AV. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosinase residues of specific protein substrates in various tumors. Proc Natl Acad Sci USA 1991;88:1656-1660.
    • Lee MT, Liebow C, Kamer AR, Schally AV. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosinase residues of specific protein substrates in various tumors. Proc Natl Acad Sci USA 1991;88:1656-1660.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.